EcoDrugPlus

Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin)

Ensembl ID : ENSOCUG00000021499
Gene Symbol: NPM1
4 Cross references
107 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSOCUG00000001033
Gene Symbol: OPRD1
3 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSOCUG00000003120
Gene Symbol: OPRK1
3 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSOCUG00000016025
Gene Symbol: OPRM1
2 Cross references
214 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSOCUG00000011285
Gene Symbol: PAK4
2 Cross references
163 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSOCUG00000029602
Gene Symbol: PNLIP
3 Cross references
294 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOCUG00000012400
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSOCUG00000009353
Gene Symbol: PPARA
3 Cross references
453 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSOCUG00000007732
Gene Symbol: PPARD
2 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOCUG00000013194
Gene Symbol: PPARG
3 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOCUG00000010631
Gene Symbol: PIK3CA
3 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSOCUG00000004899
Gene Symbol: PIK3CB
3 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).